Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Southern African Journal of Infectious Diseases

 
 
Field Value
 
Title Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
 
Creator Brink, Adrian J. Coetzee, Jennifer Richards, Guy A. Feldman, Charles Lowman, Warren Tootla, Hafsah D. Miller, Malcolm G.A. Niehaus, Abraham J. Wasserman, Sean Perovic, Olga Govind, Chetna N. Schellack, Natalie Mendelson, Marc
 
Subject Infectious diseases; Clinical microbiology; Clinical pharmacists, Pulmonology, Critical Care antimicrobial stewardship; β-lactam/β-lactamase inhibitor combinations; ceftazidime-avibactam; ceftolozane-tazobactam; Gram-negatives; Pseudomonas aeruginosa; Enterobacterales
Description Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa’s multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.
 
Publisher AOSIS Publishing
 
Contributor
Date 2022-10-20
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Review
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajid.v37i1.453
 
Source Southern African Journal of Infectious Diseases; Vol 37, No 1 (2022); 10 pages 2313-1810 2312-0053
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajid.co.za/index.php/sajid/article/view/453/1065 https://sajid.co.za/index.php/sajid/article/view/453/1066 https://sajid.co.za/index.php/sajid/article/view/453/1067 https://sajid.co.za/index.php/sajid/article/view/453/1068
 
Coverage South Africa — —
Rights Copyright (c) 2022 Adrian J. Brink, Jennifer Coetzee, Guy A. Richards, Charles Feldman, Warren Lowman, Hafsah D. Tootla, Malcolm G.A. Miller, Abraham J. Niehaus, Sean Wasserman, Olga Perovic, Chetna N. Govind, Natalie Schellack, Marc Mendelson https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT